37 results about "Oligodendrocyte differentiation" patented technology

Described is the efficient and robust generation of oligodendrocyte progenitor cells (OPCs) and oligodendrocytes from pluripotent stem cells (PSCs). The protocols provided recapitulate the major steps of oligodendrocyte differentiation, from neural stem cells to OLIG2+progenitors, and then to 04+ OPCs, in a significantly shorter time than the 120-150 days required by previous protocols. Furthermore, 04+ OPCs are able to differentiate into MBP+mature oligodendrocytes in vitro, and to myelinate axons in vivo when injected into immuno-compromised Shiverer mice, providing proof of concept that transplantation of PSC-derived cells for remyelination is technically feasible.

The invention relates to a TAT-WNK102 transmembrane protein and application thereof. The protein has an amino acid sequence shown in SEQ ID NO1. The TAT-WNK102 transmembrane protein can inhibit the combination of LINGO-1 and WNK1; and after the interaction between the LINGO-1 and the WNK1 is inhibited by the peptide, the differentiation and maturation of cultured oligodendrocytes can be promoted, thereby obtaining the TAT-WNK102 transmembrane protein. The TAT-WNK102 transmembrane protein can be used for the preparation of medicaments for treating demyelinating diseases of the central nervous system.

The invention discloses a method for preparing tissue engineering spinal cords by using mesenchymal stem cells derived from dermis, which comprises the following steps of 1) separating dMSCs, and carrying out passage on the dMSCs so as to obtain dMSCs primary cells; 2) moving the dMSCs primary cells obtained through separating to an amplification culture medium so as to carry out amplification; and 3) dropwise adding an engineering spinal cord saturated water solution into a physiological saline solution containing deep nerve nutriments, retinoic acid and Neuregulin, standing the obtained mixture, carrying out gradient alcohol dehydration on the mixture, and carrying out vacuum drying on the mixture; and infecting the dMSCs subjected to amplification by using a brain-derived neurenergen adenovirus expression vector, and inoculating cells to an engineering spinal cord material for culturing. In the method, tissue engineering spinal cords can effectively promote cell proliferation; and the differentiation rates of the tissue engineering spinal cords to nerve cells and oligodendroglia cells are respectively about 4.8% and 1.5% which are far higher than those of pure scaffold materials (the differentiation rates of pure scaffold materials to nerve cells and oligodendroglia cells are respectively 1.8% and 0.5%).

The present invention discloses the application of catalpol in promoting the differentiation of neural stem cells to oligodendrocytes, specifically using a drug concentration gradient microfluidic chip to evaluate the effect of different concentrations of natural active drug catalpol on the differentiation of NSCs to oligodendrocytes. effect. The results showed that catalpol had no toxic effect on NSCs at a concentration lower than 3 mg / mL, and catalpol could significantly promote the differentiation of NSCs into oligodendrocytes. This system provides a platform for in vitro research on the mechanism of catalpol, an active ingredient of traditional Chinese medicine, on the differentiation of NSCs oligodendrocytes. The promoting effect of catalpol, an active ingredient of traditional Chinese medicine provided by the invention, on the differentiation of NSCs oligodendrocytes provides a basis and feasible technical support for NSCs replacement therapy for central nervous system demyelinating diseases in the preclinical stage.